Getting vaccinated from shingles reduces the risk of developing dementia. Large-scale new research I’ll find it.

This result provides some of the most powerful evidence that several viral infections can affect brain function in a few years and can interfere with them.

The study, published in Nature on Wednesday, found that those who received the shingles vaccine were 20% less likely to develop dementia seven years later than those who were not vaccinated.

“If you are reducing your risk of dementia by 20%, that’s very important in the public health context. Given that there aren’t too many at this point in slowing the onset of dementia,” Dr. Harrison was not involved in the new study. Other studies The shingles vaccine indicates a lower risk of dementia.

Whether protection can exceed seven years can only be determined by further research. However, with few effective treatments or prevention currently available, Dr. Harrison said the shingles vaccine appears to have “some of the most potent potential protective effects against dementia that we know are actually potentially potentially available.”

The case of shingles comes from a virus that causes water cell-zoster, a childhood chicken pox. As the age and the immune system weakens, the virus can reactivate and cause shingles, with symptoms such as burning, tingling, painful blisters and numbness. Nerve pain can be chronic and ineffective.

In the US, 1 in 3 Develop a lifetime centre for disease control and prevention of at least one case of shingles, also known as Herpes Zoster. Approximately one-third of eligible adults have received the vaccine in recent years. According to the CDC

While several previous studies suggest that shingles vaccinations may reduce the risk of dementia, most people were unable to rule out the possibility that vaccinated individuals may have other dementia protective properties, such as a healthier lifestyle, better diet, or more education.

New research ruled out many of these factors.

“That’s very strong evidence,” said Dr. Anupam Jena, a health economist and physician at Harvard Medical School.

This study emerged from an unusual aspect of the development of the shingles vaccine in Wales on September 1, 2013. Welsh officials have established strict age requirements. That date, 79 people were eligible for the vaccine for a year, but those over 80 were ineligible. When the young people turned 79, they qualified for the vaccine for a year.

Dr. Pascal Geldsetzer, an assistant professor of medicine at Stanford University and senior author of the study, said the age cutoff was imposed because of limited supply and the vaccine was deemed ineffective to people over 80 years of age.

Scientists were able to compare relatively equal groups. I’m with people who qualify for the vaccine and people who couldn’t get it. “If you hire 1,000 people born a week and 1,000 people born a week later, there shouldn’t be any difference between them, except for the big differences in vaccinations,” Dr. Geldsetzer said.

Researchers tracked health records of around 280,000 people, ages 71-88, without dementia when the development began. Over seven years, almost half of those eligible for the vaccine received it, but only a small number of ineligible groups received it, providing a clear front-and-after distinction.

To limit the likelihood of differences between groups, researchers used statistical analysis to measure data from people who only had one week on either side of the cutoff.

They also looked at medical records for possible differences between vaccinated and non-vaccinated. They evaluated whether unvaccinated people received more dementia diagnoses and took more medications that could increase their risk of dementia simply because they visited their doctors more frequently.

“They do a pretty good job with that,” Dr. Jena said. I wrote an explanation about nature research. “They are seeing nearly 200 drugs that have been shown to be linked to an increased risk of Alzheimer’s disease at least.”

He said, “They are making a lot of effort to understand whether there may be other things to suit that age cutoff, other health policy changes, but that doesn’t seem to be the case.”

The study included Zostavax, an older form of shingles vaccine. This includes a fixed version of the live virus. It was then discontinued in the US and several other countries as protection against shingles declined over time. Singlix, a new vaccine containing the inactive portion of the virus, is more effective and permanent, research shows.

Last year’s research Dr. Harrison and his colleagues suggested that Singlix may be more protective against dementia than the older vaccine. Based on another “natural experiment,” the shift from Zostavax to Shingrix in the US in 2017 found that people who received the new vaccine for more than six years had fewer dementia diagnoses than those who received the old vaccine. Of those diagnosed with dementia, those who received the new vaccine were nearly six months longer than those who received the old vaccine, and nearly six months before they developed the condition.

There are various theories as to why the shingles vaccine protects against dementia. One possibility is that by preventing shingles, the vaccine reduces neuroinflammation caused by virus reactivation, Dr. Geldsetzer said. “Inflammation is a bad thing for many chronic diseases, including dementia,” he said.

Both new and Singlics research support that theory.

Another possibility is that vaccines will make the immune system more broad. New research also provides some evidence of that theory. Dr. Geldsetzer found that women with a more reactive immune system and greater antibody response to vaccination than men experience greater protection against dementia than men. The vaccine also provided a greater protective effect against dementia among people with autoimmune conditions and allergies.

Dr. Maria Nagel, a professor of neurology at the University of Colorado School of Medicine, was not involved in the study, but said both theories were true. “There is evidence of direct and indirect effects,” said Dr. Nagel, who consulted the manufacturer of GSK’s Shingrix.

She said that while other vaccines, including those against the flu, produce common neuroprotective effects, there are several studies that have found that it makes sense that the shingles vaccine is especially protected against cognitive impairment, as the shingles virus is hidden in the nerves.

Although this study did not distinguish between types of dementia, other studies suggest that “the effect of the shingles vaccine against Alzheimer’s disease is much more pronounced than that of another dementia.” Recent research Alzheimer’s disease and other dementia and vaccines. She said that some cases of Alzheimer’s are linked to immunity compromise.

The Welsh population in the study was mostly white, Dr. Geldsetzer said, but the report suggested similar protective effects by analyzing UK death certificates for deaths caused by dementia. His team also replicated the results in Australia, New Zealand and Canada.

Dr. Jena said there is a need to further study the connection, noting that reducing the risk of dementia is not the same as preventing all cases. Still, he suggests that the evidence “something about exposure or access to the vaccine will have this effect on the risk of dementia in a few years.”